Erica Stringer-Reasor, M.D., assistant professor in the University of Alabama at Birmingham Division of Hematology and Oncology, has been awarded a $450,000 grant from Susan G. Komen to support a clinical trial investigating PARP inhibitors for the treatment for HER2-positive breast cancer.
HER2-positive breast cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 or HER2, which promotes the growth of cancer cells. In about one of every five breast cancers, the cancer cells have a gene alteration that makes an excess of the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other breast cancers.
PARP is an enzyme in cells that helps repair DNA when it has become damaged, as in the case with cancer. PARP inhibitors work by keeping cancer cells from repairing themselves once they have been damaged by chemotherapy, while sparing healthy cells.
At UAB, Eddy Yang, M.D., Ph.D., professor and vice chair of Translational Research in the UAB Department of Radiation Oncology, discovered that PARP inhibitors may be particularly effective in HER2-positive breast cancer that has become resistant to anti-HER2 therapies.
“However, medications are still being tested in clinical trials, and are not yet FDA-approved for use outside of clinical research,” said Andres Forero, M.D., professor in the UAB Division of Hematology and Oncology, and head of the breast cancer research program.
Stringer-Reasor’s grant will allow her to investigate the combination of PARP inhibitors with HER2-positive targeted therapies, which could improve patient survival.
“There is some evidence that different PARP inhibitors work differently, so not all may have similar results in clinical trials,” said Forero, a senior scientist at the UAB Comprehensive Cancer Center. “We are conducting the next level of research using combination therapies to get better outcomes and move the needle forward.”
The Breast Cancer Research Foundation of Alabama (BCRFA) presented two awards for two-year collaborative breast cancer research projects. One award went to Dr. Gary Piazza of the University of South Alabama Mitchell Cancer Institute and Dr. Clinton Grubbs of the University of Alabama – Birmingham Comprehensive Cancer Center with the second award going to Drs. Joel Berry, Jessy Deshane and Andra Frost of UAB and Dr. Mark Suto of Southern Research Institute.
Proposals from across the state were reviewed in September and the winners were announced at the UAB Comprehensive Cancer Center Annual Research Retreat on October 30.
Piazza and Grubbs’ project, “A Novel Wnt/β-Catenin Inhibitor for Breast Cancer,” will focus on developing a promising experimental drug, MCI-030, for breast cancer prevention and treatment and further study its unique mechanism of action involving the suppression of Wnt/β-Catenin signaling.
Berry, Deshane, Frost and Suto’s project, “A Humanized 3D Immunocompetant Model of Breast Cancer for Precision Medicine and Immune Therapy Development” will develop a 3D humanized immunocompetent breast cancer model that will enhance cancer drug development and advance personalized cancer therapy.
The selected projects will each receive $50,000 annually for two consecutive years, totaling $100,000 each over the two- year period. The BCRFA will also continue a second year of support for the inaugural award to Sara Cooper, PhD, of HudsonAlpha Institute for Biotechnology, and Donald Buchsbaum, PhD, of UAB. Cooper and Buchsbaum’s project is characterizing the effects of immunotherapy in breast cancer models and explore new drugs to improve immune system response
The Breast Cancer Research Foundation of Alabama is a nonprofit organization raising funding and awareness for breast cancer research in Alabama.
“Since the organization began in 1996, the BCRFA has invested over $6.75 million in breast cancer research initiatives in Alabama. We are excited to award these two grants supporting collaborative breast cancer research,” stated Beth Bradner Davis, BCRFA executive director.
With these collaboration awards, the Breast Cancer Research Foundation of Alabama hopes to: encourage collaboration among top researchers in Alabama in the field of breast cancer research; help support basic research which can be emerge into translational research; offer financial support to promising breast cancer research in Alabama providing seed money to enable a project to secure additional funding from national providers; and offer hope to those affected by breast cancer and ultimately save lives through breast cancer research.
About the BCRFA
The Breast Cancer Research Foundation of Alabama supports a comprehensive approach to battling breast cancer through support of collaborative and innovative research to help diagnose, treat, prevent and eradicate the disease. Since its inception in 1996, the BCRFA has raised over $6.75 million to fund research at the UAB Comprehensive Cancer Center and with their collaborative partners. All funds raised stay here in the state of Alabama, but the research will have a global, life-saving impact. BCRFA.org
With record attendance of more than 400 participants, fourteen UAB scientists and two Mitchell Cancer Institute researchers were selected for awards during the UAB Comprehensive Cancer Center’s 19th Annual Research Retreat. This year the event focused on the prevalent research area of Metabolism and Cancer.
The research competition enables junior investigators, resident trainees, postdoctoral fellows and graduate students to showcase their research in cancer prevention and control, biostatistics and bioinformatics, among other areas. The 2017 competition included 136 poster presentations. Awards were given in eight categories.
Ralph Sanderson, Ph.D., professor in the UAB Department of Pathology and co-leader of the Cancer Cell Biology Program at the UAB Comprehensive Cancer Center, received the Albert F. LoBuglio Distinguished Faculty Award. This award is presented annually by the director to a Cancer Center investigator who has made outstanding research contributions.
The John R. Durant Award for Excellence in Cancer Research was presented in three categories. Junior Investigator winners were Mohamed Khass, Ph.D., Renata Jaskula-Sztul, Ph.D. and Bing Zhu, Ph.D. of the Mitchell Cancer Institute. Resident Trainee/Postdoctoral Fellow winners were Shannon M. Kahan, Ph.D., Shyam Kumar Bandari, Ph.D., and Angela M. Carter, Ph.D. Graduate student winners were Caroline W. Cohen, M.S., Ph.D., Asmi Chakraborty, M.S., and Tejeshwar Rao, Ph.D.
Adam B. Keeton, Ph.D. of the Mitchell Cancer Institute, received the William C. Bailey Award for Excellence in Cancer Prevention and Control Research, with honorable mentions for Jacqueline B. Vo, Ph.D., and Karina Halilova, M.D., M.P.H.
Ritesh K. Srivastava, Ph.D., received the Tandra Chaudhuri Award for Excellence in Cancer Research.
The Seng-jaw Soong Award for Excellence in Biostatistics and Bioinformatics Research was presented to Sean M. Santos, B.S., and Amena R. Alkeswani received the Cancer Research Experiences for Students (CaRES) Award.
In addition, the Breast Cancer Research Foundation of Alabama also presented two awards for two-year collaborative breast cancer research projects. The selected projects will receive $50,000 annually for two consecutive years, totaling to $100,000 each. One award went to Gary A. Piazza, Ph.D. of the University of South Alabama Mitchell Cancer Institute and Clinton J. Grubbs, Ph.D. of the UAB Comprehensive Cancer Center with the second award going to Joel Berry, Ph.D., Jessy Deshane, Ph.D., and Andra R. Frost, M.D. of UAB and Mark J. Suto, Ph.D. of Southern Research Institute.
University of Alabama at Birmingham School of Nursing Associate Dean for Research and Scholarship and Professor Karen Meneses, Ph.D., has been appointed to the National Institute of Nursing Research’s National Advisory Council for Nursing Research (NACNR), where she will directly impact the NINR’s continuing mission to promote and improve the health of the nation’s individuals, families and communities.
Meneses is co-director of the school’s Doctor of Philosophy in Nursing program — the only one in the state — and will serve on the 15-member NACNR, which meets three times a year to help guide NINR’s direction, through 2021.
“It is truly an honor for me personally to be named to a national advisory board for NINR,” Meneses said. “This is also recognition of the UAB School of Nursing and its impact as an institution of nursing research. It is a tribute to being a nurse and a researcher, and I believe it will bring even more acknowledgment of the work we do here at the UAB School of Nursing and universitywide.”
She will provide recommendations to the NINR director about the direction and support of research that serves as the evidence base for nursing practice.
To achieve its mission, the NINR supports and conducts clinical and basic research and research training on health and illnesses. This research spans and integrates the behavioral and biological sciences and helps develop the scientific basis for clinical practice.
Written by Matt Windsor for The UAB Mix
The tumor is in the salivary gland, and it’s a tough one. All the typical treatments thrown at it have failed. With nothing left to try, the patient’s doctor turns to a pioneering new kind of cancer program at UAB: the Molecular Tumor Board.
The MTB, led by Eddy Yang, M.D., Ph.D., launched in 2013. It was funded by UAB Hospital and Blue Cross Blue Shield of Alabama to pay for gene sequencing in difficult cases like these. Sequencing can cost $4,000 or more, and because there is little available research on efficacy, insurers don’t usually cover it. But Blue Cross and UAB Hospital, like nearly everyone else in health care, appreciate the potential of gene sequencing in patient care. It’s up to groundbreaking programs like Yang’s MTB to help set the standard for how sequencing becomes part of standard practice.
The doctors send a small sliver of tumor to a specialized lab in St. Louis, where scientists look for mutations in more than 100 cancer-associated genes. A few weeks later, Yang has a hit.
The patient’s tumor turns out to be driven by a mutation in the BRAF gene. BRAF makes a protein, B-Raf, that signals cells to grow. That means the tumor cells are overproducing B-Raf and turbocharging their growth rate. This is actually good news. The doctors have drugs that block BRAF — they’re used to treat the skin cancer melanoma. So the MTB recommends a combination of BRAF inhibitors and MEK inhibitors, a related therapy.
“The cancer responded pretty well,” recalls Yang, who is ROAR Southeast Cancer Foundation Endowed Chair in Radiation Oncology, professor and vice chairman for translational science in the Department of Radiation Oncology and the UAB Comprehensive Cancer Center, and deputy director of the UAB Hugh Kaul Precision Medicine Institute. “The patient was in remission for more than a year.”
Cancer is a disease with a thousand faces. Oncologists like Eddy Yang have to recognize which one they’re seeing with each new patient. In the last few years, the job has gotten both easier and harder. There are now hundreds of drugs available to treat cancer — as well as new tools like gene sequencing to help doctors find the most appropriate treatment for each patient.
But these tools have also demonstrated that cancer comes in many more varieties than the 100 or so named types, which are generally labeled by the organ where they are found. There isn’t just “breast cancer” or “uterine cancer,” for instance — there’s breast cancer driven by a BRCA2 mutation, and uterine cancer driven by a KRAS mutation. In May 2017, the FDA approved the drug Keytruda (pembrolizumab) to treat metastatic solid tumors with microsatellite instability — the first time any regulatory agency approved a drug based on a molecular target rather than a specific tissue type.
“The goal of precision oncology is not to think about cancer according to its type, but as a cancer with a specific defect or driver,” such as a BRAF mutation, says Yang. In an intriguing new paper, Yang and colleagues report on three years worth of data from the MTB. It provides a glimpse into the future of medicine.
“Better treatment options”
During that three-year window, 191 cases were discussed at the MTB, and 132 cases were approved for testing. Out of 124 cases with results available:
- 46 patients had predictive or prognostic mutations.
- The most common mutation site was the tumor suppressor gene TP53.
- 56 patients had mutations reported in cancer (but with no current predictive or prognostic significance).
- The number of mutations present in those two groups ranged from 1–6.
- 22 patients had no clinically significant mutations.
The results make clear that “sequencing isn’t a magical cure at this point,” Yang says. “We’re not going to find drugs for every person whose tumor we sequence.” Some mutations aren’t targeted by any current drugs, or may require a combination of treatments that hasn’t been identified yet. But the MTB experience, Yang says, demonstrates that “we may be able to offer better treatment options for some patients.”
New opportunities at UAB
More patients have the option to receive sequencing, at no cost, thanks to UAB’s participation in the Strata Trial. Patients with metastatic or unresectable tumors, glioblastoma multiforme or pancreatic cancer, or a rare cancer are eligible to participate in the trial. Tumors are sequenced at no cost, with doctors selecting the most appropriate therapy based on the results. Another UAB-affiliated study, the TAPUR trial run by the American Society of Clinical Oncology, gives patients access to more than a dozen new targeted therapies.
More than 300 patients at UAB have been sequenced as part of the Strata Trial. “We are now sequencing 50–60 patients per month,” Yang says. At this point, the “hit rate” — patients who have an actionable mutation — is around 70 percent. Of those, around 20 percent will get an offlabel drug or be enrolled in a clinical trial of a new drug, Yang notes. For a sizable number, sequencing lets doctors “know what drugs not to give,” he adds. For instance, patients with colon cancer are often treated with the drug cetuximab. “But if you have a KRAS mutation, we don’t use cetuximab,” Yang says.
The new standard of care
For patients with lung cancer, melanoma and colorectal cancer, the value of genetic sequencing for stage IV tumors upfront has already been demonstrated, Yang says. Insurance companies cover testing costs, and doctors specializing in these conditions now routinely order sequencing.
“That’s the beauty of trials like Strata,” Yang explains. “For lung and colon cancer, ordering sequencing is now almost reflexive for doctors. Now at UAB, we can be reflexive for other types of cancer as well. Precision medicine is our standard of care.”
Written by Matt Windsor for The UAB Mix
Every cancer treatment, whether it’s an experimental drug or a trusted standby, comes at a cost. There is the literal cost, in dollars. “But schedules, toxicities, the burden on a family or other caregivers,” are all part of the equation as well, says Gabrielle Rocque, M.D., an assistant professor in the UAB School of Medicine Division of Hematology and Oncology and UAB Comprehensive Cancer Center.
Rocque specializes in the treatment of metastatic breast cancer. Thirty percent of women with early stage breast cancer develop recurrent or metastatic disease, when the cancer has spread to other organs and is much more complicated to treat (typically because it has become resistant to the first-line treatments). More than 150,000 women in the United States are now living with metastatic breast cancer. Every year, more than 40,000 will die from the disease, but the median survival is now more than two years.
“That number continues to increase as new treatment options become available,” Rocque says. (See Game-changing therapies.) The growing number of therapies make treatment of metastatic breast cancer very complex. “There are different options for what you can do at any given time,” Rocque says. And each has its own schedule of required clinic visits, follow ups and side effects, she adds. “For patients with a limited life expectancy, hours spent in hospitals and clinics may cost them valuable time with their loved ones.”
In two new studies, Rocque is examining how to give patients a more informed role in those treatment decisions.
With a grant from the American Cancer Society (ACS), Rocque is piloting a new model for shared decision making in metastatic breast cancer using treatment plans. These are documents, written in lay language, that provide patients with a game plan for their care. “Treatment plans have not been tested in metastatic cancer, where they may provide the greatest benefit,” Rocque noted in her grant application.
As part of its participation in the Oncology Care Model program from the Center for Medicare and Medicaid Innovation, UAB is already using software called Carevive to give patients treatment plans once treatment begins. With her ACS study, Rocque is testing what happens when patients have input before the plan is set. To begin, she and her team are interviewing patients, patient navigators, nurses and physicians at UAB to gather a picture of the most important topics to consider, including personal and treatment goals, along with concerns such as being a burden to others.
“These are patients who are going to be on treatment for the rest of their lives,” says Rocque. “It’s important to consider both quantity and quality of life.”
Rocque will use information from these patient interviews to create an electronic treatment planning tool, then test it in a randomized controlled trial against the current standard of care. Follow-up surveys will examine how the treatment plans affect patients’ experience of shared decision making in their care.
Previous studies of treatment plans in other diseases have found that both patients and their providers appreciate having these tools available. But the costs of implementing treatment plans are an important factor in adoption as well, Rocque notes. “Any change has to work for all participants in the health-care system, including patients, providers and payers, such as insurance companies,” she says. “Otherwise it’s not sustainable.” So Rocque is also conducting an economic analysis as part of her study. New Medicare rules are tying doctor’s payments to a number of metrics, including patients’ rating of shared decision making. Rocque’s analysis will examine whether the costs of software and time involved in treatment planning will be outweighed by improved payments from Medicare and other payers.
The entire national debate about health-care revolves around financial costs. But surprisingly little is known about the true costs of metastatic breast cancer care, in money and time, Rocque says. She is looking to fill that gap with an unprecedented analysis — a combination of Medicare and private claims data, patient surveys, and a process known as time-driven activity-based costing, which charts how long each step takes in a clinic visit, from the wait at reception to the consultation with the oncologist and any treatment infusions.
“We’re tracking anything that a patient is doing related to health-care that is taking up time,” says Rocque. “That includes the time it takes to drive to appointments, going to pick up prescriptions, talking to staff on the phone to set up future visits.” By charting the staff time involved in each step of the treatment cycle, Rocque will also be able to quantify the true cost of treatment to a health system.
The study, funded by a grant from biotechnology company Genentech, will feed invaluable data to doctors that they can use to improve care, Rocque says. “We don’t talk to patients a lot about how much time and effort some of these treatments require,” she notes. “That’s because we don’t have a great idea of the magnitude of time involved.
“If someone is going on a clinical trial, we know that will take more time, but how much? It may be where we’ll be able to say, ‘There are two different treatments available: over the next six months, on one you’ll spend 20 hours in the clinic, and with the other, you’ll spend 150 hours in the clinic.’ That might be something patients really care about, and I’ve never seen people be able to quantify that. It won’t be perfect, but it will give them an idea.”
Last week, the University of Alabama at Birmingham treated brain cancer patients for the first time utilizing Varian HyperArc™ High-Definition Radiotherapy, making the academic medical center the first in the United States to use this technology for complex radiosurgical procedures.
With HyperArc, which Varian Medical Systems tested and partly developed in collaboration with UAB, clinicians can deliver more compact radiation doses that closely conform to the size, shape and location of brain cancer tumors while sparing more surrounding healthy tissue.
About 20-40 percent of cancer patients will develop brain metastases. More than half of them will have more than one tumor in the brain. The risk of a metastatic brain tumor depends on the kind of cancer and how advanced it is when it is diagnosed. Typically, an increasing number of patients return for retreatment of their disease.
“HyperArc allows us to plan and deliver state-of-the-art radiosurgery to highly complex cases efficiently with a very high degree of dose compactness and conformity, and has made it possible to treat patients with larger numbers of brain metastases very aggressively,” said John Fiveash, M.D., professor and vice chair for academic programs in the UAB Department of Radiation Oncology. He is also a senior scientist at the UAB Comprehensive Cancer Center.
“Five radiosurgery patients were treated with HyperArc therapy the first day,” Fiveash said. “Most of these patients had multiple brain metastases. We were impressed with the quality and efficiency of the plan creation and treatment delivery. Patients are excited to be treated in a normal time slot of 15-20 minutes without the requirement of an invasive stereotactic head frame.”
HyperArc contains a prescriptive workflow that includes simulation guidelines, patient immobilization, treatment planning, patient setup, imaging and pre-determined delivery sequence.
“HyperArc allows us to irradiate multiple tumors at the same time without repositioning the patient, which provides better management of patient movement while saving time for the patient and the clinical team,” Fiveash said.
“Basically, HyperArc is designed to enable consistent, high-quality planning and seamless one-click delivery,” said Richard Popple, Ph.D., professor and assistant vice chair for Physics in the UAB Department of Radiation Oncology. He is also an expert in novel treatment planning techniques and clinical implementation of new technologies and a senior scientist at the UAB Comprehensive Cancer Center.
HyperArc addresses concerns about complexity, patient safety, cost and human resources that can make radiosurgery inaccessible for many patients and unfeasible for many institutions.
“Working closely with leading institutions like UAB played an important role in the development of HyperArc,” said Kolleen Kennedy, president of Varian’s Oncology Systems business. “We value their continued contributions to the advancement of cancer care, and we are excited that HyperArc treatments have now begun in the U.S.”
Planning through the workflow
For the past several years, UAB has been working with Varian to bring HyperArc technology to fruition. UAB has been involved with four other institutions in developing optimization tools to enhance the dose and treatment delivery. They developed dedicated algorithms to ensure efficient workflow, and new ways of looking at multiple targets simultaneously, all while reducing the complexity of the planning process for clinicians. In addition, UAB helped devise metrics to use for single and multiple targets that can be customized.
Maximizing cost and efficacy
“We are able to help more patients without the need to invest in additional or new equipment,” Popple said. HyperArc capitalizes on the unique capabilities of Varian’s TrueBeam™ and EDGE™ treatment systems, which UAB already uses.
The advanced HyperArc treatment can be completed within a conventional treatment timeslot, making it an efficient approach compared to other radiosurgery techniques that treat each target individually or separately and take considerably longer.
Addressing patient safety
Patient safety was a central pillar in the product design philosophy. “Fully automated treatments present operational challenges because of patient safety concerns,” Popple said. “We address this challenge by using virtual dry runs and collision avoidance systems integrated into the treatment machine.” Specifically calculated arcs and couch positions are compatible with patients’ clearance to the machine. Even the hardware that the patient wears is digitally modeled in the treatment planning system for safe delivery and ensuring minimal patient movement.
Moving the needle in brain surgery
Tumors in the brain are usually distributed throughout the brain and can affect many basic functions, making it one the most complex of all surgeries. This technique provides an alternative targeted approach when surgery might not be possible, or the tumor is located in a compromising area.
“HyperArc treats all the patient’s tumors at once, allowing for a more efficient and comfortable radiosurgery procedure,” said Bart Guthrie, M.D., professor in the UAB Department of Neurosurgery. “Since we can easily treat more than 10 tumors, more patients will be able to avoid the cognitive side effects of whole brain radiation therapy.”
“We are very excited about these first treatments using HyperArc as we usher in a new era of precision in radiotherapy and radiosurgery for cancer patients,” Fiveash said. “Bottom line, we want to be able to make high-quality treatments available to more patients. We want to capitalize on this technology because ultimately it’s our patients who benefit from the most advanced care possible.”
Story from UAB Medicine News
UAB Medicine cancer survivor Kirstin Hoff creates art to raise awareness, support charities, and lift spirits through volunteer work at The Kirklin Clinic and elsewhere.
When Kirstin Hoff was diagnosed with breast cancer in 2013, she chose right then to focus on the positive. It was a good strategy, not only because what she calls “a spirit of hope and joy” comes naturally to her, but also because her journey from diagnosis to survivorship met many obstacles. Without the positive attitude that Hoff would maintain through each level of treatment or setback, her experience might have been far more difficult. After getting through that struggle, however, she decided to go even further by utilizing her positive energy for the benefit of other cancer patients and their families. She established Chick4acause, her very own private mission of hope and joy.
The “chick” refers to the whimsical characters of her mixed media paintings of chickens, each of which includes found “treasures” attached to the work. Hoff’s non-profit company Chick4acause is promoted via social media, and proceeds from the sale of any works go to four cancer organizations. Customers may select which organization receives proceeds from any purchase they make. As Hoff insists, however, the mission goes well beyond the matter of fundraising.
“My mission is less about raising money and more about setting an example,” Hoff says. “I hope patients see that, after my own battle with breast cancer, I’m energetic and fully engaged with volunteer work at The Kirklin Clinic, awareness work, and fundraising. I hope I’m an example of survivorship as well as a messenger.
My main message is that our little efforts of kindness and joy can make a difference. I would like to show others that, very often, if we choose the mood and outlook of that journey, then we aren’t letting cancer make all the decisions. I’m hoping to form a community of people who can share their own stories about making positive choices.”
Hoff understands the benefits of making those choices, because she ran into what she calls “roadblocks” at various points in treatment.
“I was hospitalized with a C. diff infection at one point, serious enough that, while I was in intensive care, the doctors were wondering if I would survive it. I came down with shingles while getting radiation treatment. We kept hitting every obstacle that my body could find. But I chose to focus on the good things surrounding that terrible situation. The number of people supporting me, and the friends and family looking after my kids, were blessings that I kept in mind. I tried to go through this with the most positive, joyful attitude I could manage.”
Hoff says she wasn’t sure what to expect after being diagnosed with ductile and metastatic breast cancer, being unfamiliar with the vocabulary of cancer, her options, and what approach her doctors might take. After meeting with an interdisciplinary team at UAB’s Comprehensive Cancer Center, under the care of Andres Ferero, MD, and Helen Krontiras, MD, Hoff was relieved to learn that the team shared her upbeat attitude.
“It’s sad to say, but before I was immersed in this world of cancer, I didn’t even know about UAB’s center,” Hoff notes. “I can’t fully convey the emotional impact of my team’s positive energy. It was a source of comfort and security, almost like I had an entire army fighting for me. Their approach instantly put me at ease. My team completely sympathized with my desire to delay chemotherapy until our family could get back from a beach trip. I think they knew, especially under those circumstances, how important that vacation would be to us. I also had tickets to a concert. The doctors understood that I needed some positive moments of joy and normalcy before treatment started. Dr. Ferero has this unbelievable energy; he’s so supportive and upbeat, so passionate about his work, and so humble. I don’t think I have the words to express how much he means to me.”
She may not have found words yet, but Hoff did find a way to express her personal message of joy and hope. Hoff says the means of doing so was there all along.
“I had been painting these chickens as art gifts for friends and family during the holidays. I started paying attention to people who visited my house during December who might say, ‘I would purchase one of those,’ or ‘I didn’t know you painted.’ It sort of clicked with me that I could sell this artwork as a fundraiser. I wanted the chicks to be whimsical and fun, but with a message of hope. Each piece has a special personalized “surprise” on the back to get the joy started for someone. So I apply items to each painting that convey these things, such as re-purposed children’s clothes, or re-purposed books I find at thrift stores that have positive quotes or messages.”
Very soon after her treatment, Hoff was determined to get involved with volunteer work at The Kirklin Clinic, as well as creating Chick4acause and sharing her story of survivorship. Her first efforts were with The Angel Squad, a group of volunteers who offer compassionate services to breast cancer patients and their caregivers.
“When I was undergoing treatment, the interaction with my Angel and the others was incredible. I started working with them as soon as I was well enough. From that point I wanted to find a way to make an impact by spreading some kind of positive message. The world, especially recently, already seems filled with negativity, and that’s a big driving point. You can get caught up in the larger view and see yourself as insignificant. How could you possibly make a difference? But the mission grows over time. I now have four organizations that proceeds go to. I’ve also sent pieces to Arizona and Canada for charities that conduct silent auctions. I’m getting so much response by word of mouth and through Facebook and Instagram.”
Hoff insists that the fundraising effort is by no means the whole story of her work. She sees her mission to build awareness and establish a community of story-sharing survivors as the primary function of her efforts. For Hoff, the small measures add up.
“It’s something I’m trying to teach my kids right now. Don’t wait for the big opportunity for some huge project. Do the little things. My 13-year-old daughter goes with me to visit elderly residents of memory care facilities with the Good Samaritan groups from our church; my 12-year-old son goes with me to thrift stores to search for little treasures and objects we can attach to the paintings. They are learning about the satisfaction and joy these small efforts can bring. I have tried to emphasize that everyone has some gift or ability that they can use.
“My kids also have a sense of humor about me and my mission, which is its own kind of joy. The other day my daughter asked, ‘Mom, why do you have to turn everything into a life lesson?’ You have to be able to laugh about it. But I still believe in choosing your role. I have a piece of art I found at Southern Makers that reads, ‘Kindness is a choice. It’s not a random act.’ That speaks to me so deeply. This is how we make neighborhoods or hospitals or schools a happier, healthier place to be. More than that, I think it’s contagious. Even the individual who buys one of the chicks gets a measure of joy by contributing to a good cause. They have, in a sense, been brought into a community where hope and joy are so vital and crucial to any of us dealing with cancer.”
Hoff still faces a long-term regimen of medication and checkups, but she’s approaching that with the same hope and upbeat demeanor with which she tackles all the work that Chick4acause entails. She says her appreciation for the community of survivors grows as well.
“I think everyone goes through it in their own way,” she says. “I know how many people have undergone much more intense radiation, harsher chemo, and greater loss than I have. I lost my mother to colon cancer last year. My mother-in-law battled with intestinal cancer. My message is that it’s much more bearable if we make the effort to share hope. When I’m working with the Angel Squad, or if I’m in mammography or in the clinic, I tell patients I meet that I let my doctors do the worrying while I put as much joy and happiness into my life as possible. That’s the partnership that I feel I have established with UAB. They know what they are doing, so I trust them. I never think in terms of breast cancer recurrence, or ‘what if.’ They have a wealth of knowledge, so they don’t need me for the medical end of handling my care. I handle the cheerleading!”
Mona N. Fouad, M.D., professor and director of the Division of Preventive Medicine in the University of Alabama at Birmingham School of Medicine, has been elected as a member of the National Academy of Medicine — one of the highest honors given to a physician or scientist in the United States.
This honor acknowledges a lifetime of exceptional work in health and medicine. Fouad is nationally recognized as a leader in health disparities research and collaboration. Her work generates and combines research from biomedical, behavioral and social sciences in an interdisciplinary approach to address health disparities. Her impact among the national community of scholars — especially young scholars from diverse, underrepresented backgrounds — has spread beyond her institution to touch others in alleviating these disparities among vulnerable populations.
“I’m thrilled and humbled to be elected to the prestigious National Academy of Medicine,” said Fouad, who directs the UAB Minority Health and Health Disparities Research Center. “It is a tremendous honor to be recognized.”
The National Academy of Medicine, established in 1970 under the name Institute of Medicine, is an independent organization of eminent professionals from diverse fields including health and medicine — the natural, social and behavioral sciences — and beyond. Membership in NAM is widely viewed as one of the highest honors in the fields of health and medicine, and is limited to individuals who have demonstrated both exceptional professional achievements and outstanding commitment to service.
“This is a singular honor for Dr. Fouad’s body of work, and all of us at UAB are very proud of her and this prominent recognition she has received,” said UAB President Ray L. Watts, M.D.
“In her career, Dr. Fouad has a huge impact in her interdisciplinary approach toward the elimination of health disparities,” said Selwyn M. Vickers, M.D., senior vice president for Medicine and dean of the UAB School of Medicine. “As both the dean and a frequent collaborator with Dr. Fouad’s research efforts, I’m pleased that Mona’s career is being honored in a way that truly highlights her accomplishments.”
Fouad’s career at UAB began in 1991 as an instructor in the Department of Medicine. In 2002, she became the founding director of the Minority Health and Health Disparities Research Center — a universitywide interdisciplinary research center. She was promoted to full professor in 2005, and in 2009 became director of the division of Preventive Medicine. From 2003 to 2013, she served as co-leader of the Cancer Control and Population Science Program in the UAB Comprehensive Cancer Center, and she is currently senior adviser to the Cancer Center director. She is also a member of the Diabetes Research and Training Center, the Nutrition Obesity Research Center, the Center for Outcomes and Effectiveness Research and Education, and the Comprehensive Center for Health Aging. In 2005, she was named the inaugural chair of the Commission on the Status of Women at UAB, a position she held until 2008. She was named senior associate dean for Diversity and Inclusion in the School of Medicine in 2013.
Fouad has worked tirelessly to establish the validity of health disparities as a national scientific research priority. There has been an unprecedented expansion of health disparities research at UAB and in collaborative relationships with national and international grant partners, as well as an increase in the number of researchers and young scholars pursuing careers in minority health and health disparities.
Fouad plays a prominent leadership role in a partnership among historically black colleges and universities to train minority researchers and leaders to eliminate health disparities. She serves as the principal investigator for the NIMHD-funded Centers of Excellence, in which she is responsible for the training and career development of minority students and faculty to enhance their research capabilities. Under Fouad’s leadership, the MHRC has been continually funded as a National Institute on Minority Health and Health Disparities Centers of Excellence for the past 15 years.
Fouad’s work as an innovative scientist is complemented by her accomplishments in academic publication. In January 2017, Fouad was one of three co-editors for the American Journal of Preventive Medicine, Vol. 52, Social Determinants of Health: An Approach to Health Disparities Research. Also, in 2014, She served as co-editor of Cancer Supplement Vol. 120, Enhancing Minority Participation in Clinical Trials (EMPaCT). She served on the scientific committee for the 2014 International Symposium on Minority Health and Health Disparities and wrote more than 120 publications, all with a focus on health disparities research.
Fouad has served in myriad local, national and international leadership positions for a variety of organizations. She has served as a member of the NIH National Advisory Council on Minority Health and Health Disparities and the American Cancer Society Mid-South Division Board of Directors. For six years, Fouad was commissioner of the Black Belt Commission, appointed by former Alabama Governor Bob Riley. She is an external advisory board member of the Gulf South Minority/Underserved NCI Community Oncology Research Program, Louisiana State University, and the Centre for Health and Development, Staffordshire University, U.K.
Her achievements have been recognized nationally as a recipient of the American Cancer Society St. George National Award in 2016, recognizing her distinguished service to achieving the ACS’ strategic goals and the 2016 President’s Council on Fitness, Sports and Nutrition Community Leadership Award for exemplary service and dedication to improving the lives of others by promoting and fostering opportunities for participation in fitness, sports and nutrition programs. Fouad was also named one of the 2016 “Women Who Shape the State” by the Alabama Media Group.
“I’m tremendously proud of Dr. Fouad and grateful to count her as a colleague and leader at UAB,” said C. Seth Landefeld, M.D., chair of the UAB Department of Medicine. “In her work, in her writing and in her leadership, Dr. Fouad has opened eyes to disparities in health and health care, and she has pioneered efforts to reduce these disparities — contributions that change our world.”
Through its domestic and global initiatives, NAM works to address critical issues in health, medicine and related policy, and inspire positive action across sectors. NAM collaborates closely with its peer academies and other divisions within the National Academies of Sciences, Engineering and Medicine
University of Alabama at Birmingham Hospital has received a 2017 Women’s Choice Award for being one of America’s Best Breast Centers in the United States. This evidence-based designation was given to UAB based on robust criteria that consider female patient satisfaction and clinical excellence.
The Women’s Choice Award is a referral source empowering women to make informed health care decisions by identifying the country’s best health care institutions. Its seal portrays a symbol of empowerment for all women and signifies the strength and power of today’s female consumer.
“We take great pride in receiving this honor, especially since it comes from the women we have cared for,” said Helen Krontiras, M.D., director of the UAB Division of Surgical Oncology and medical director of the UAB Breast Health Center. “We now know that breast cancer is not a one-size-fits-all disease, and we strive to provide each woman the most appropriate plan that is suited for her specific need.”
According to the American Cancer Society, breast cancer is the second most common form of cancer among women. One in eight women will develop invasive breast cancer during her lifetime. In Alabama alone, 4,000 new cases will be diagnosed this year.
Award winners must meet the high standards of the National Accreditation Program for Breast Centers from the American College of Surgeons, and also carry the Breast Imaging Center of Excellence seal from the American College of Radiology.
In addition, the breast centers associated with a hospital, such as UAB, had to receive a rating in the top 75 percent for the Centers for Medicare and Medicaid Services’ patient recommendation measures, or their equivalent in the case of breast centers without hospital affiliation.
The UAB Breast Health Center is part of the UAB Comprehensive Cancer Center, one of the nation’s leading cancer research and treatment centers, and is the only National Cancer Institute-designated comprehensive cancer center located in the four-state area that includes Alabama, Arkansas, Louisiana and Mississippi. “We created the America’s Best Breast Center Award to empower women to make smart decisions for their breast care, from their very first screening to treatment if cancer is found,” said Delia Passi, founder and CEO of the Women’s Choice Award and a breast cancer survivor. “Based on my own unfortunate experience, I know the importance of choosing an accredited center with top-quality care to give women the greatest chance for a positive outcome.”
“When women choose the UAB Breast Health Center, they can be confident in knowing that our physicians are nationally recognized experts in breast health and employ today’s leading-edge treatments,” Krontiras said.
Located at The Kirklin Clinic of UAB Hospital, the breast health center takes a multidisciplinary approach providing the patient with a specialized medical team, including a medical oncologist, radiation oncologist and surgical oncologist, on the same day to discuss options and ask questions. Along with the expertise of the physician team, patient care is combined with nurse practitioners, navigators, social workers and a variety of other supportive services, including nutritional, genetic and fertility counseling, physical and massage therapy, and support programs for patients to meet other survivors.
View the complete list of 2017 awardees.